Search
Statistics
We have 222 registered usersThe newest registered user is raheelmemon
Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
FDA Approves Inhaled Antipsychotic (Loxapine)
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psycho-Pharmacology
Page 1 of 1
FDA Approves Inhaled Antipsychotic (Loxapine)
Admin Sat Dec 17, 2011 1:23 am
FDA Approves Inhaled Antipsychotic (Loxapine)
Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted to recommend that ADASUVE(TM) (Staccato® loxapine) be approved for use as a single dose in 24 hours when used with the FDA recommended Risk Evaluation and Mitigation Strategy (REMS), for the treatment for agitation in patients with schizophrenia or bipolar mania.
About ADASUVE (Staccato loxapine) and the Staccato System
ADASUVE is an anti-agitation product candidate that combines Alexza's proprietary Staccato system with loxapine, an antipsychotic currently available in the U.S. as an oral formulation for the management of schizophrenia. The Staccato system is a hand-held, single-dose inhaler that delivers a medication comparable to intravenous administration, but with greater ease, patient comfort and convenience. In clinical studies, ADASUVE has shown an onset of effect in 10 minutes of dosing, which is the first time point measured in the Phase 3 clinical studies. The ADASUVE NDA contains efficacy and safety data from more than 1,600 patients and subjects, who have been studied in thirteen different clinical trials.
Source:http://nocache-phx.corporate-ir.net/phoenix.zhtml?c=196151&p=RssLanding&cat=news&id=1638940
Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted to recommend that ADASUVE(TM) (Staccato® loxapine) be approved for use as a single dose in 24 hours when used with the FDA recommended Risk Evaluation and Mitigation Strategy (REMS), for the treatment for agitation in patients with schizophrenia or bipolar mania.
About ADASUVE (Staccato loxapine) and the Staccato System
ADASUVE is an anti-agitation product candidate that combines Alexza's proprietary Staccato system with loxapine, an antipsychotic currently available in the U.S. as an oral formulation for the management of schizophrenia. The Staccato system is a hand-held, single-dose inhaler that delivers a medication comparable to intravenous administration, but with greater ease, patient comfort and convenience. In clinical studies, ADASUVE has shown an onset of effect in 10 minutes of dosing, which is the first time point measured in the Phase 3 clinical studies. The ADASUVE NDA contains efficacy and safety data from more than 1,600 patients and subjects, who have been studied in thirteen different clinical trials.
Source:http://nocache-phx.corporate-ir.net/phoenix.zhtml?c=196151&p=RssLanding&cat=news&id=1638940
Admin- Admin
- Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia -
Similar topics» FDA Rejects Loxapine for Approval
» Significance of Loxapine and Glycosuria ?
» FDA Approves New Paroxetine Formulation: Brisdelle
» FDA Approves First Insomnia Drug- Intermezzo
» FDA approves shared system REMS for TIRF products
» Significance of Loxapine and Glycosuria ?
» FDA Approves New Paroxetine Formulation: Brisdelle
» FDA Approves First Insomnia Drug- Intermezzo
» FDA approves shared system REMS for TIRF products
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psycho-Pharmacology
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
» L-Methylfolate: Who Will benefit
» Vitamins & Supplements in Clinical Practice.
» Imaging Biomarkers for Outcomes in Mild TBI
» Q.5 Clozapine Neutopenia
» Treating Disorders!
» Cortical Abnormalities in Adults & Adolescents with MDD
» Efficacy of Antipsychotics in Pediatric Acute Mania
» Obsessive Compulsive Disorder in Adults: Which Treatment is Better?